Sign in to view content

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2

Emily Y. Chew, MD

Video
Published 2023

Related

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes with Nonexudative AMD Trial (PREVENT): A Prospective Controlled
Maziar Lalezary, MD, FASRS
Updates from the Field
2018
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023

Category: Retinal Vascular Disease

See more